Tumor Immunology and Immunotherapy

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
The AACR has designated this live activity for a maximum of 18.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, November 15, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives
In 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US. Almost 40% of men and women will be diagnosed with cancer during their lifetimes. While surgery, chemotherapy and radiotherapy have been the mainstay of cancer treatments, these have significant side effects and are often ineffective. Novel, safe and tolerable therapeutic approaches are greatly needed.

Utilizing the body’s immune system to fight cancer is often safer and better tolerated than traditional cancer treatments such as chemotherapy and radiation. Study and understanding of the immune system’s response to cancer has increased exponentially over the past several years, and this has given rise to many breakthrough cancer treatments. Types of immunotherapies include monoclonal antibodies (including checkpoint inhibitors), adoptive cell transfer (including CAR T cell therapy), therapeutic vaccines, cytokines, and oncolytic viruses.

Current promising treatments include monoclonal antibodies; radio- or chemolabeled monoclonal antibodies; bispecific monoclonal antibodies; checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of many cancers; cancer vaccines for treatment and prevention, cytokines such as interleukins and interferons; and immunomodulatory drugs that boost immune system function.

This conference will feature some of the world’s premier oncologists who will present their latest research on current immunotherapies. It will also help bridge the gap between the advances that are underway in the lab and their application to clinical practice. Particularly, this conference will feature talks from scientists working in cutting edge fields such as neoantigens and synthetic biology, as well as different perspectives of metabolism, the microbiome, and whole systems biology, which will lead to a deeper understanding of the immune response to cancer.

Physicians require a solid and current understanding of immunology to stratify patients according to tumor type and the characteristics of their tumor microenvironments, predict responses and determine the best personalized treatment plan. In addition, it has recently become apparent that conventional therapies (surgery, chemotherapy, and radiotherapy), as well as targeted agents, affect the patient’s immune system. An improved understanding of these effects will enable physicians to treat patients more effectively.

After participating in this CME activity, physicians should be able to:

1. Identify and integrate novel strategies for visualizing tumors.

2. Evaluate novel biomarkers or neoantigens, and genomics to assess patients’ individual cancer, potential responses to treatment

3. Explain the role of the gut and metabolism in tumor progression.

4. Explain the role of immunomodulatory cells in inflammation and in the tumor microenvironment

5. Integrate novel combination therapies and engineered immune cells for personalizing cancer immune responses.​

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgement of Financial or Other Support
This activity is supported by grants and will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at 215-440-9300 or​​​